CTX-130
CRISPR Therapeutics AG
['cobaltlym']
#crisprtherapeutics presents positive results from its phase 1 #cobaltlym trial of #ctx130 in #relapsed or #refractory #tcell #malignancies at the #eha22 $crsp 
Follow top-line development in the oncology commercial domain. Gain entry to KOL discussions, including both medical professionals and business leaders.